Bacillus coagulans MTCC 5856 for MDD and IBS Symptom Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current probiotic therapies lack specific evidence for the protective effects of individual strains, making it challenging to effectively treat conditions like Major Depressive Disorder (MDD), particularly in individuals with Irritable Bowel Syndrome (IBS), as health benefits are strain-specific and require individual characterization.
Innovation Solution
The use of Bacillus coagulans MTCC 5856 is proposed for therapeutic management of MDD, administered at a dose of 2×10^9 cfu/day, demonstrating its efficacy in reducing symptoms and serum myeloperoxidase levels in patients with IBS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard antidepressant therapy is used, then some symptoms of depression are reduced, but only 50-60% of patients respond to therapy and 30-40% never achieve symptom resolution
Solution Approach 1:
The patent introduces probiotics as an intermediary substance to modulate the gut microbiota, which in turn affects the gut-brain axis to improve depressive symptoms. This mediator approach addresses the limitation of direct antidepressant therapy by acting through a biological pathway (gut microbiota modulation) that complements traditional neurochemical approaches.
Solution Approach 2:
The patent changes the therapeutic parameter from direct central nervous system action (antidepressants) to gut microbiota composition modification (probiotics). By altering the microbial ecosystem parameters in the gut, the therapy aims to produce systemic effects including mood improvement, thereby addressing treatment resistance through a different physiological parameter space.
2Reliability
If probiotic therapy is used to manage stress responses and anxiety, then health benefits may be conferred, but lack of complete evidence for each potential probiotic strain makes it challenging to effectively treat specific conditions
Solution Approach 1:
The patent segments the broad category of probiotics into specific strains (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175), recognizing that different strains have different efficacy profiles. This segmentation allows for targeted therapy based on strain-specific properties rather than treating all probiotics as equivalent.
Solution Approach 2:
The patent identifies a combination of two probiotic strains that together provide multiple therapeutic benefits for depression, including mood improvement, sleep quality enhancement, and reduction of inflammatory markers. This multi-functional approach addresses several aspects of depressive symptomatology simultaneously.
3Measurement precision
If probiotic strains are tested for each property, then strain-specific health benefits can be established, but the complexity and time required for complete characterization increases
Solution Approach 1:
The patent performs preliminary in vitro screening of probiotic strains to identify those with potential antidepressant properties before conducting in vivo studies. This preliminary characterization includes assessing growth characteristics, metabolic activity, and preliminary biological effects, which helps narrow down the candidate strains for more extensive testing.
Solution Approach 2:
The patent employs a continuous, multi-stage evaluation process that progresses from in vitro screening to in vivo animal studies and finally to clinical trials. This continuous action ensures that strains are systematically characterized across multiple levels of complexity, building upon previous findings rather than repeating tests.
Data Source
AI summary
The present invention discloses the use of probiotics for therapeutic management of major depressive disorder (MDD). Specifically, the invention discloses the method of therapeutically managing MDD in mammals with Irritable bowel syndrome using probiotic strain Bacillus coagulans MTCC 5856.